Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Cardiac protection by pharmacological modulation of inflammation
Autore:
Latini, R; Masson, S; Bertini, R; Maggioni, AP; Ghezzi, P; Calvillo, L;
Indirizzi:
Mario Negri Inst Pharmacol Res, Dept Cardiovasc Res, I-20157 Milan, Italy Mario Negri Inst Pharmacol Res Milan Italy I-20157 I-20157 Milan, Italy
Titolo Testata:
EXPERT OPINION ON INVESTIGATIONAL DRUGS
fascicolo: 11, volume: 10, anno: 2001,
pagine: 1913 - 1924
SICI:
1354-3784(200111)10:11<1913:CPBPMO>2.0.ZU;2-O
Fonte:
ISI
Lingua:
ENG
Soggetto:
ACUTE MYOCARDIAL-INFARCTION; C-REACTIVE PROTEIN; ISCHEMIA-REPERFUSION INJURY; SECONDARY PREVENTION TRIAL; ACUTE-PHASE RESPONSE; KAPPA-B ACTIVATION; SUPEROXIDE-DISMUTASE; IN-VIVO; INTRACORONARY ADENOSINE; ENDOTHELIAL-CELLS;
Keywords:
adenosine; antibiotics; atherosclerosis; chemokines; cytokines; inflammation; myocardial ischaemia; neutrophils; PMN; reperfusion; statins;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
115
Recensione:
Indirizzi per estratti:
Indirizzo: Latini, R Mario Negri Inst Pharmacol Res, Dept Cardiovasc Res, Via Eritrea62, I-20157 Milan, Italy Mario Negri Inst Pharmacol Res Via Eritrea 62 Milan Italy I-20157
Citazione:
R. Latini et al., "Cardiac protection by pharmacological modulation of inflammation", EXPERT OP I, 10(11), 2001, pp. 1913-1924

Abstract

Inflammation is a reaction to primary injury of various kinds, such as infection and trauma, which has both beneficial and detrimental effects. inflammation has been associated with major diseases of the heart and vessels. Research has focused not only on ischaemia but also on post-ischaemic reperfusion, which is known to activate and amplify the inflammatory response. Although reperfusion should always be attempted in the clinical environment, it has been shown experimentally that it can cause some cardiac damage, in addition to that caused by ischaemia. Therefore, it is reasonable to attempt to increase the benefit obtainable with reperfusion by modulating inflammatory processes triggered by reperfusion itself. In this field, different potential therapeutic targets have been identified and interventions have been tested over the last 30 years. With the exception of adenosine, which probably does not act merely through inhibition of the inflammatory response,no other compounds have yet proven successful in clinical trials. Active research is ongoing. Broadening the approach from the heart to the cardiovascular system, promising data is emerging on cardiovascular protection conferred by statins in patients with coronary heart disease (CHD) and high levels of C-reactive protein (CRP), a systemic marker of inflammation. Similarly, results of trials aimed at preventing cardiovascular events by eradicating chronic infections will be among the first to directly test whether suchtherapies will decrease risks of cardiovascular disease.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/04/20 alle ore 23:57:14